CJC-1295
A long-acting GHRH analog often discussed with ipamorelin.
The short version
- Why people discuss it
- AxonRep’s community research identifies recurring interest in CJC-1295 around growth-hormone signaling, body composition, recovery, sleep and pairing with ipamorelin. Those repeated themes extend beyond the limited human trials.
- What it is
- The studied CJC-1295 is a long-acting GHRH analog with a drug-affinity complex that binds albumin. Community use of “CJC-1295 without DAC” may refer to a shorter-acting modified GRF peptide and is not the same preparation.
- Biggest caution
- FDA flags immunogenicity and peptide-impurity concerns and reports serious adverse events including increased heart rate and a systemic vasodilatory reaction. Small healthy-volunteer studies do not establish long-term benefit or safety.
- Stack context
- Ipamorelin is frequently paired with CJC-1295 in community discussion, but repetition does not establish that the combination improves outcomes or has a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Sources report different amounts or schedules; the reference below is a named example, not a consensus.
Subcutaneous injection; with DAC
Community reference · Not clinical guidance- Amount
- 1–2 mg total per week
- Frequency
- Once or twice weekly
- Duration / phase
- 8–12 weeks
Identity-specific pattern; without-DAC products use different schedules Reference only; this does not establish safety, effectiveness or individual suitability.
Reference source · reviewed 2026-09-12Modified GRF 1-29 — “CJC without DAC”, subcutaneous
Community reference · Not clinical guidance- Amount
- 100–200 mcg per administration
- Frequency
- Once or twice daily
- Duration / phase
- 8–12 weeks
Distinct short-acting preparation. Human DAC studies do not validate a no-DAC regimen; do not use the DAC weekly amount on a daily schedule.
Community source · reviewed 2026-09-27Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
DAC 2 mg once/week OR 0.3→1 mg twice/week for 8–12 weeks; no-DAC 0.1→0.3 mg daily, 8–12 weeks.
- Peptidepedia — saved source reviewed September 27, 2026
DAC 0.3–0.6 mg once/twice weekly; no-DAC 0.1–0.2 mg 1–2 times/day, 8–12 weeks.
Evidence & sources · Limited human evidence
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- FDA: CJC-1295 compounding safety concernsRegulatory source · Checked 2026-09-12
- PubMed: randomized CJC-1295 pharmacology trials in healthy adultsExisting research · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27
- Peptidepedia — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27